PMID: 6894267Nov 1, 1980Paper

Studies on heart. II. Further effects of bovine ventricle protein (BVP) and antiarrhythmic peptide (AAP) on myocardial cells in culture

Chemical & Pharmaceutical Bulletin
S AonumaS Iwasaki

Abstract

No abstract listed.

Citations

Antiarrhythmic peptide has no direct cardiac actions

Aug 15, 1989·Experientia·T ArgentieriJ R Wiggins

Peptides acting at gap junctions

Sep 10, 2002·Peptides·Stefan Dhein

Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40

Feb 5, 2003·Biology of the Cell·Stefan DheinJaques Antoine Haefliger

ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs

Jun 5, 2003·Journal of Cardiovascular Electrophysiology·Dezhi XingJames B Martins

Drug development for treatment of cardiac arrhythmias: targeting the gap junctions

Sep 25, 2007·American Journal of Physiology. Heart and Circulatory Physiology·Andrew L Wit, Heather S Duffy

Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride (GAP-134)13, an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation

Jan 30, 2009·Journal of Medicinal Chemistry·John A ButeraJørgen S Petersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Related Papers

ContactHelpTerms Privacy Cookies
© 2022 Meta ULC. All rights reserved